Zhongguancun announced that the “National Essential Drug Catalogue” came into effect on September 1. Fourteen of the company's subsidiaries have been included in the catalogue. This time, 4 new varieties have been added and 1 variety has been withdrawn. Sales revenue of the company's strategic product oxycodone hydrochloride injection increased 121.95% year-on-year in 2025, and its entry into the “Basic Drug Catalogue” will strengthen the company's advantage. The introduction of new products will help expand coverage and is expected to have a positive impact on long-term development, but drug sales are affected by various factors, and there is uncertainty.

Zhongguancun announced that the “National Essential Drug Catalogue” came into effect on September 1. Fourteen of the company's subsidiaries have been included in the catalogue. This time, 4 new varieties have been added and 1 variety has been withdrawn. Sales revenue of the company's strategic product oxycodone hydrochloride injection increased 121.95% year-on-year in 2025, and its entry into the “Basic Drug Catalogue” will strengthen the company's advantage. The introduction of new products will help expand coverage and is expected to have a positive impact on long-term development, but drug sales are affected by various factors, and there is uncertainty.